<![CDATA[Abstract: Chronic kidney disease (CKD) is closely associated with hyperuricemia. Allopurinol is recommended for patients with CKD stages 2–5 to reduce serum uric acid levels, although its renoprotective effects may vary depending on patient characteristics. This study aimed to obtain changes in serum uric acid and estimated glomerular filtration rate (eGFR) in CKD patients receiving allopurinol therapy at Prof. Dr. R. D. Kandou Hospital Manado during 2021–2024. A retrospective longitudinal descriptive design was employed. As an exploratory purpose, pre–post therapeutic analyses and subgroup comparisons were conducted. The results showed that the greatest reduction in serum uric acid was observed among patients aged 30–65 years, males, those with type 1 diabetes mellitus, and individuals with stage G5 CKD. Increases in eGFR were noted in patients aged <30 years, females, and those with rheumatic heart disease as a comorbidity. Conversely, decreases in eGFR were found in patients aged ≥30 years, males, those with liver cirrhosis, and individuals in CKD stages G2–G3. In conclusion, changes in serum uric acid and eGFR among CKD patients receiving allopurinol vary according to age, sex, comorbidities, and stage of CKD. Keywords: chronic kidney disease; hyperuricemia; allopurinol Abstrak: Penyakit ginjal kronis (PGK) berhubungan erat dengan hiperurisemia. Alopurinol direkomendasikan pada pasien PGK stadium 2-5 untuk menurunkan kadar asam urat, meskipun efek renoprotektifnya dapat bervariasi menurut karakteristik pasien. Penelitian ini bertujuan mendeskripsikan perubahan kadar asam urat dan estimasi laju filtrasi glomerulus (eLFG) pada pasien PGK pengguna alopurinol di RSUP Prof. Dr. R. D. Kandou Manado periode 2021–2024. Jenis penelitian ialah deskriptif longitudinal retrospektif. Sebagai tujuan eksploratif, dilakukan analisis pre–post terapi serta komparatif antar-subkelompok. Hasil penelitian mendapatkan penurunan kadar asam urat terbesar pada kelompok usia 30–65 tahun, laki-laki, komorbid diabetes melitus tipe 1, dan stadium G5. Peningkatan eLFG terjadi pada kelompok usia <30 tahun, perempuan, dan komorbid penyakit jantung rematik. Sebaliknya, penurunan eLFG terlihat pada kelompok usia ≥30 tahun, laki-laki, kelompok komorbid sirosis, serta stadium G2–G3. Simpulan penelitian ini ialah perubahan kadar asam urat dan eLFG pada pasien PGK yang menggunakan alopurinol bervariasi menurut usia, jenis kelamin, komorbid, dan stadium PGK. Kata kunci: penyakit ginjal kronis; hiperurisemia; alopurinol]]>
Copyrights © 2026
